Nektar Therapeutics (NKTR) News

Nektar Therapeutics (NKTR)

Today's Latest Price: $16.53 USD

0.06 (-0.36%)

Updated Oct 1 11:48am

Add NKTR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 376 in Biotech

See all "A" rated Strong Buy stocks

Filter NKTR News Items

NKTR News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest NKTR News From Around the Web

Below are the latest news stories about Nektar Therapeutics that investors may wish to consider to help them evaluate NKTR as an investment opportunity.

Earnings Preview: Nektar Therapeutics (NKTR) Q2 Earnings Expected to Decline

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2020

Hedge Funds Aren’t Impressed By Nektar Therapeutics (NKTR)

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | June 24, 2020

Edited Transcript of NKTR.OQ earnings conference call or presentation 7-May-20 9:00pm GMT

Q1 2020 Nektar Therapeutics Earnings Call

Yahoo | June 15, 2020

Why Is Nektar (NKTR) Up 12% Since Last Earnings Report?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | June 6, 2020

Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)

Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a potential therapeutic for a range of autoimmune disorders, including systemic lupus erythematosus (SLE).

Yahoo | June 4, 2020

Nektar Therapeutics to host webcast on NKTR-358 data June 5

Following the virtual presentation of Phase 1b data on candidate NKTR-358 in systemic lupus erythematosus patients at EULAR 2020, Nektar Therapeutics (NKTR) will host a webcast and conference call on Friday, June 5, at 11:00 am ET to discuss the results....

Seeking Alpha | May 30, 2020

7 Stocks Maverick Capital Continues to Buy

Adobe and Avantor make the list Continue reading...

Yahoo | May 26, 2020

Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal

Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery on BEMPEG, a CD122-preferential IL-2 pathway agonist, demonstrated that when administered as a monotherapy, it was well tolerated and showed clinical activity, including tumor shrinkage and durable disease stabilization, in heavily pretreated patients with solid tumor cancers.1 The manuscript published today presents the safety, immune-activation and efficacy results from a Phase 1 dose-escalation study conducted in 38 patients with immunotherapy-naïve, advan...

Yahoo | May 22, 2020

Oppenheimer Sticks to Their Hold Rating for Nektar Therapeutics

Oppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Sunday, setting a price target of $25, which is approximately 13.53% above the present share price of $22.02.

Yahoo | May 17, 2020

Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript | The Motley Fool

NKTR earnings call for the period ending March 31, 2020.

The Motley Fool | May 8, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7266 seconds.